

Org. No: 556966-4955
February 24, 2022



Elicera Therapeutics' Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET's Educational Day 2022

Gothenburg, February 24, 2022 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company that develops next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced that the company's Chief Scientific Officer (CSO) and co-founder, Professor Magnus Essand, will present at SWECARNET's Educational Day on April 27th, 2022.

SWECARNET, Sweden's network for clinical use of CAR T-cells, will hold an Educational Day on April 27th, 2022, where Elicera's CSO, Professor Magnus Essand, will hold a presentation on the topic: *What will research bring in the future?*

More information and the program can be found here:

<https://atmpsweden.se/events/swecarnet-utbildningsdag-2022/>

Registration can be done here: <https://www.eventbrite.com/e/swecarnet-utbildningsdag-biljetter-265001345157>

For further information please contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB

Phone: +46 (0) 703 31 90 51

jamal.elmosleh@elicera.com

About SWECARNET

SWECARNET is Sweden's network for clinical use of CAR T-cells.

SWECARNET was established in 2019 by the SDP5 Swelife-ATMP project of the same name.

Coordinated by the Centre for Cell therapy and Allogeneic Stem cell Transplantation (CAST) at Karolinska University Hospital, the network brings together those in Sweden developing, implementing or treating patients with Chimeric antigen receptor T (CAR T) cells

Network partners: Uppsala Universitet, Skånes Universitetssjukhus, Sahlgrenska Universitetssjukhuset, Karolinska Institutet, Karolinska Universitetssjukhuset, Novartis Sverige AB, Celgene AB/BMS, Gilead Science Sweden AB, Jansen-Cilag AB and Läkemedelsindustriföreningen

About Elicera Therapeutics AB

Elicera Therapeutics AB is a clinical stage cell and gene therapy company that develops next generation immuno-oncology treatments based on enhanced oncolytic viruses and CAR T-cells. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T-cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T-cells in development and activate killer T-cells against cancer. The company's share (ELIC) is traded on Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: ca@gwkapital.se, tel: +468-503 000 50.

For more information, please visit www.elicera.com